87233-62-3 | Emedastine difumarate

Packsize	Purity	Availability	Price	Discounted Price
5mg	≥98%	in stock	$42.00	$29.00
10mg	≥98%	in stock	$79.00	$55.00
250mg	98%	in stock	$106.00	$75.00
1g	98%	in stock	$175.00	$122.00

Description

• Catalog Number: AH90219
• Chemical Name: Emedastine difumarate
• CAS Number: 87233-62-3
• Molecular Formula: C25H34N4O9
• Molecular Weight: 534.5589
• MDL Number: MFCD00923844
• SMILES: OC(=O)/C=C/C(=O)O.OC(=O)/C=C/C(=O)O.CCOCCn1c(nc2c1cccc2)N1CCCN(CC1)C

Computed Properties

• Complexity: 460
• Covalently-Bonded Unit Count: 3
• Defined Bond Stereocenter Count: 2
• Heavy Atom Count: 38
• Hydrogen Bond Acceptor Count: 12
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9

Literature

• The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.

  Acta haematologica 20110101

• Contribution of mast cells to cerebral aneurysm formation.

  Current neurovascular research 20100501

• Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.

  Acta ophthalmologica 20090801

• Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases.

  Expert opinion on pharmacotherapy 20090801

• Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.

  Experimental eye research 20080501

• Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts.

  Journal of investigational allergology & clinical immunology 20080101

• High-performance liquid chromatography-electrospray ionization-mass spectrometric determination of emedastine difumarate in human plasma and its pharmacokinetics.

  Journal of chromatographic science 20070301

• [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis].

  Orvosi hetilap 20070211

• Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial.

  European journal of dermatology : EJD 20060101

• Estimation of in vivo percutaneous absorption of emedastine from bile excretion data using a deconvolution method.

  Drug metabolism and pharmacokinetics 20051001

• Biopharmaceutical considerations on antihistamine effects of topically administered emedastine.

  Journal of pharmaceutical sciences 20050101

• [Topical H1 antihistaminics in the therapy of acute conjunctival allergic reactions].

  Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 20040101

• Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis.

  Arzneimittel-Forschung 20040101

• Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis.

  Arzneimittel-Forschung 20040101

• Suplatast tosilate inhibits eosinophil production and recruitment into the skin in murine contact sensitivity.

  Clinical immunology (Orlando, Fla.) 20030901

• Development of a new dissolution test method for an oral controlled release preparation, the PVA swelling controlled release system (SCRS).

  Journal of controlled release : official journal of the Controlled Release Society 20030605

• [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children].

  Orvosi hetilap 20030406

• [In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].

  Journal francais d'ophtalmologie 20030401

• Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis.

  Skin pharmacology and applied skin physiology 20030101

• Pharmacokinetic and mass balance study of unlabelled and (14)C-labelled emedastine difumarate in healthy volunteers.

  Xenobiotica; the fate of foreign compounds in biological systems 20020901

• Effect of antiallergic drugs on interleukin 5-induced eosinophil infiltration of rat airways.

  Biological & pharmaceutical bulletin 20020301

• Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females.

  Journal of psychopharmacology (Oxford, England) 20020301

• Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.

  Clinical therapeutics 20020301

• A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.

  Clinical therapeutics 20020301

• Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes.

  Journal of dermatological science 20020101

• Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.

  European journal of ophthalmology 20020101

• Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.

  American journal of ophthalmology 20010601

• VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.

  Japanese journal of pharmacology 20010501

• Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment.

  European journal of clinical pharmacology 20010301

• Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers.

  International journal of clinical pharmacology and therapeutics 20010301

• Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries.

  PharmacoEconomics 20010101

• Effect of emedastine difumarate on CC chemokine-elicited eosinophil migration.

  International archives of allergy and immunology 20010101

• General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st communication: effects on the central nervous system.

  Arzneimittel-Forschung 19880101

• Pharmacologic analysis of LY188695 (KB-2413), 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole difumarate, a potent histamine1 receptor antagonist.

  Agents and actions 19870201